Loading...
Loading...
India's aspirin imports from THAILAND total $5.5K across 1 shipments from 1 foreign suppliers. MS NOVACYL SAS leads with $5.5K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include RITSA PHARMA PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for aspirin โ a concentrated sourcing relationship with select suppliers from THAILAND.

MS NOVACYL SAS is the leading Aspirin supplier from THAILAND to India, with import value of $5.5K across 1 shipments. The top 5 suppliers โ MS NOVACYL SAS โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MS NOVACYL SAS | $5.5K | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | RITSA PHARMA PRIVATE LIMITED | $5.5K | 1 | 100.0% |
THAILAND โ India trade corridor intelligence
The Thailand to India trade corridor has experienced fluctuations in port congestion, particularly at major ports like Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra. Freight rates have varied, influenced by global shipping trends and regional factors. The exchange rate between the Thai Baht and the Indian Rupee has impacted the cost-effectiveness of imports from Thailand. Between 2025 and 2026, these factors have contributed to changes in the dynamics of the trade corridor, affecting the timeliness and cost of shipments.
The Production Linked Incentive (PLI) scheme has been a significant factor in India's push for self-reliance in pharmaceutical manufacturing. This initiative aims to reduce dependency on imports by incentivizing domestic production. Import substitution policies have been implemented to encourage local manufacturing of pharmaceutical products, including Aspirin formulations. These policies may impact the volume of finished formulation imports from Thailand, as domestic production capabilities are enhanced.
The trade relationship between India and Thailand has been strengthened through Free Trade Agreement (FTA) negotiations and mutual recognition of Good Manufacturing Practices (GMP). These agreements have facilitated smoother trade processes, including the import of pharmaceutical products. Pharmaceutical trade facilitation measures have been implemented to streamline customs procedures and ensure the quality and safety of imported drugs. These bilateral efforts aim to enhance the efficiency and reliability of the pharmaceutical supply chain between the two countries.
The landed cost of importing finished pharmaceutical formulations containing Aspirin from Thailand to India includes several components:
Per-unit estimates can be calculated by summing these components and dividing by the total number of units imported.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Aspirin into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the foreign manufacturer and the product be registered. The foreign manufacturer must possess a valid manufacturing or wholesale drug license from their home country. The product must be registered with CDSCO, which involves submitting an application along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration process typically takes several months, depending on the completeness of the application and the evaluation process. For formulations under HS Code 30049062, specific requirements include compliance with the Indian Pharmacopoeia standards and submission of batch-wise stability data. An Import License from the Directorate General of Foreign Trade (DGFT) is also required, which necessitates obtaining an Importer Exporter Code (IEC) and fulfilling other DGFT formalities. The timeline for obtaining the import drug registration and license can vary but generally spans several months.
Imported finished pharmaceutical formulations containing Aspirin must undergo quality testing to ensure they meet Indian standards. Batch-wise testing is mandatory, and each batch must be accompanied by a Certificate of Analysis (CoA) issued by the manufacturer. The CoA should confirm that the product complies with the specifications outlined in the Indian Pharmacopoeia. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's stability under Indian climatic conditions. Upon arrival at Indian ports, customs drug inspectors conduct inspections to verify the authenticity of the documents and the quality of the products. If any discrepancies or quality issues are identified, the batch may be detained, and further testing may be required. Failure to meet the required standards can result in rejection of the batch and potential penalties for the importer.
Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements between India and Thailand have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline the import process for Thai manufacturers. Additionally, the CDSCO has updated guidelines for the registration of imported drugs, emphasizing the need for comprehensive stability data and adherence to Indian pharmacopoeia standards. These changes aim to enhance the quality and safety of imported pharmaceutical products.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Aspirin formulations to meet the demand for specific dosage forms and branded products not manufactured domestically. The domestic pharmaceutical industry may lack the capacity to produce certain specialized formulations, leading to reliance on imports. The market size for Aspirin formulations in India is substantial, with a growing demand for both over-the-counter and prescription products. Imports play a crucial role in fulfilling this demand, especially for high-quality and branded Aspirin formulations.
The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049062 is 10%. In addition to BCD, the Social Welfare Surcharge (SWS) is applicable, calculated as a percentage of the BCD. The Integrated Goods and Services Tax (IGST) is also levied on imported goods, including pharmaceutical products. Anti-dumping duties may apply if the Directorate General of Trade Remedies (DGTR) determines that imports are being dumped in the Indian market. Exemption notifications may apply under specific conditions, such as for products imported for charitable purposes or under certain trade agreements. The total landed duty percentage combines BCD, SWS, and IGST, impacting the final cost of imported products.
India sources finished Aspirin formulations from Thailand due to competitive advantages such as the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Thai manufacturers may offer unique formulations or packaging that are not produced domestically. Other suppliers, including China, Germany, and the United States, also export Aspirin formulations to India. Thailand's share in the Indian market is influenced by factors such as product quality, pricing, and regulatory compliance.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished Aspirin formulations from Thailand due to strategic reasons such as the availability of patented formulations, specialized dosage forms, and technology-licensed products. Specific formulations that Thailand supplies, which India does not manufacture, include certain branded products and unique dosage forms. These imports fulfill market demands that are not met by domestic production capabilities.
When compared to other origins like China, the European Union, and the United States, Thailand offers competitive advantages in terms of price, quality, regulatory compliance, and reliability. Thai manufacturers adhere to international quality standards and offer products at competitive prices. The regulatory compliance and reliability of Thai suppliers make them a preferred choice for Indian importers seeking consistent quality and timely delivery.
Indian importers face several supply chain risks when sourcing finished pharmaceutical formulations from Thailand. Single-source dependency can lead to supply disruptions if the supplier faces issues. Currency fluctuations between the Thai Baht and the Indian Rupee can impact costs. Regulatory changes in either country can affect import procedures and costs. Quality incidents, such as batch rejections, can lead to financial losses and reputational damage. Shipping disruptions, including port congestion or logistical challenges, can delay deliveries. Past shortages have occurred due to unforeseen events affecting production or shipping.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Aspirin suppliers from THAILAND to India include MS NOVACYL SAS. The leading supplier is MS NOVACYL SAS with import value of $5.5K USD across 1 shipments. India imported Aspirin worth $5.5K USD from THAILAND in total across 1 shipments.
India imported Aspirin worth $5.5K USD from THAILAND across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Aspirin sourced from THAILAND include RITSA PHARMA PRIVATE LIMITED. The largest buyer is RITSA PHARMA PRIVATE LIMITED with $5.5K in imports across 1 shipments.
The total value of Aspirin imports from THAILAND to India is $5.5K USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists